Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I1VK
|
|||
| Drug Name |
Heterocyclic-substituted 3-alkyl azetidine derivative 2
|
|||
| Synonyms |
PMID26161824-Compound-159
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H26F2N6O
|
|||
| Canonical SMILES |
CC(C)(C(C1CN(C1)C(C2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C4=NN=C(O4)N)C5=CC(=CC(=C5)C#N)F)F
|
|||
| InChI |
1S/C30H26F2N6O/c1-30(2,32)26(23-10-19(15-34)11-25(31)13-23)24-16-38(17-24)27(20-8-6-18(14-33)7-9-20)21-4-3-5-22(12-21)28-36-37-29(35)39-28/h3-13,24,26-27H,16-17H2,1-2H3,(H2,35,37)
|
|||
| InChIKey |
AKSVEYGFHNXCSL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.